Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP
Status:
Terminated
Trial end date:
2020-01-16
Target enrollment:
Participant gender:
Summary
Multicentre, open label, uncontrolled, phase I pharmacokinetic study, to determine the
Maximum Tolerated Dose (MTD) of APO010 administered intravenously on D1, D8 and D15 followed
by a one-week drug rest, in patients with multiple myeloma for who have relapsed or are
refractory to 2 (in high-risk patients 1) or more different prior therapies and who have Drug
Response Predictor (DRP) for APO010 indicating a higher likelihood for response to APO010.
The study will contain an extension phase where the recommended Dose will be tested on
additional patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Allarity Therapeutics Oncology Venture
Collaborators:
Medical Prognosis Institute A/S Smerud Medical Research International AS